SOURCE: Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

February 26, 2014 09:00 ET

Arch Therapeutics to Present at The Wall Street Analyst Forum Institutional Investor Conference

Company Presentation Will Be Webcast Live on Monday, March 3rd at 12:05 PM EST

WELLESLEY, MA--(Marketwired - Feb 26, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, MD, is scheduled to present a corporate overview at The Wall Street Analyst Forum Conference in Manhattan at The University Club of NYC on Monday, March 3rd at 12:05 PM EST.

The Arch Therapeutics presentation will be provided via a live audio and high-definition video webcast and can be accessed at either of the following links: or The presentation will be available on the Arch website following the event at

Arch Therapeutics recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. You will require a Microsoft Silverlight viewer (a free download from the presentation link) to participate.

About The Wall Street Analyst Forum Conferences

Our March 2014 investor conference is our 24th Annual Investor Conference. We have been a leading sponsor of institutional investor conferences in New York City, Boston and London since 1989. Over 2200 corporations, from General Electric, Pfizer, Mattel to Nokia, have presented. Institutional investors from 2000 money management firms have attended. In 1998 we received extensive coverage in the financial press for conducting the first live webcast of individual corporate meetings from an investor conference.

About Arch Therapeutics, Inc. (OTCQB: ARTH)
Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures. Find out more at

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at

On Behalf of the Board,
Terrence W. Norchi, MD
Arch Therapeutics, Inc.

Contact Information